← Biofrontera Inc.
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $18.8m |
$24.1m
+27.86%
|
$28.5m
+18.43%
|
$34.1m
+19.38%
|
$37.3m
+9.54%
|
$41.7m
+11.75%
|
$43.2m
+3.59%
|
|
| Revenues, related party | — | — | $133k | $66k | $18k | — | — | |
| Product revenues, net | — | $24.0m | $28.5m | $34.0m | $37.3m | $41.7m | — | |
| Cost of Revenue | $8.0m |
$10.2m
+27.86%
|
$12.1m
+18.43%
|
$17.4m
+43.98%
|
$18.6m
+6.67%
|
$11.0m
-41.08%
|
$9.8m
-10.51%
|
|
| Net Interest Income | — | — | ($203k) |
($560k)
-175.86%
|
($2.0m)
-263.39%
|
($452k)
+77.79%
|
($471k)
-4.20%
|
|
| Gross Profit | $10.8m |
$13.9m
+27.86%
|
$13.5m
-2.75%
|
$16.6m
+23.26%
|
$18.7m
+12.55%
|
$30.7m
+64.27%
|
$33.4m
+8.61%
|
|
| Interest Income (Expense), Net | ($2.9m) |
($344k)
+88.01%
|
($195k)
+43.31%
|
($468k)
-140.00%
|
— | — | $71k | |
| Research And Development | — | — | $0 | $77k | $2.1m | $3.7m | $3.4m | |
| Selling, general and administrative, related party | $411k | $697k | $733k | $152k | $42k | $619k | $40.7m | |
| Selling, General and Administrative Expense | $17.7m | $36.5m | $35.1m | $39.0m | $33.8m | $37.8m | $40.7m | |
| Amortization of Intangible Assets | $418k | $418k | $418k | $418k | $329k | — | — | |
| Restructuring And Mergern Acquisition | — | ($650k) | ($3.8m) | $100k | $0 | — | $0 | |
| Restructuring Costs | $1.1m | $800k | $0 | — | — | — | — | |
| Operating Expenses | $28.5m | $49.3m | $47.3m | $56.7m | $54.5m | $53.1m | $53.9m | |
| Loss from operations | ($9.6m) |
($25.2m)
-162.35%
|
($18.6m)
+26.27%
|
($22.7m)
-22.04%
|
($17.2m)
+24.11%
|
($11.3m)
+34.06%
|
— | |
| Other Non Operating Income Expenses | — | — | $69k | ($3k) | $158k | $388k | — | |
| Operating Income (Loss) | ($9.6m) |
($25.2m)
-162.35%
|
($18.6m)
+26.27%
|
($22.7m)
-22.04%
|
($17.2m)
+24.11%
|
($11.3m)
+34.06%
|
($10.7m)
+5.45%
|
|
| Interest Expense | $2.9m | $344k | $195k | $220k | ($2.0m) | ($452k) | $471k | |
| Interest Expense, Debt | — | $2k | — | — | — | — | $471k | |
| Interest Expense Non Operating | — | — | $370k | $600k | $2.0m | $452k | $471k | |
| Interest Income, Other | — | — | $10k | $132k | — | — | $71k | |
| Interest Income | — | $16k | $175k | $132k | $71k | — | $71k | |
| Net Non Operating Interest Income Expense | — | — | ($203k) | ($560k) | ($2.0m) | ($452k) | ($471k) | |
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | — | $7.2m | $98k | — | — | |
| Gain (Loss) on Investments | — | — | $1.7m | ($7.4m) | ($14k) | $2k | — | |
| Gain (Loss) Related to Litigation Settlement | — | — | — | $7.4m | — | — | — | |
| Gain On Sale Of Security | — | — | $18.1m | ($4.4m) | $1.7m | $901k | $134k | |
| Income (Loss) from Equity Method Investments | — | — | $1.7m | ($7.4m) | ($14k) | $2k | — | |
| Other Nonoperating Income (Expense) | $1.6m | $689k | $33k | ($75k) | $158k | $388k | — | |
| Other Income Expense | — | — | $22.0m | $3.0m | $1.5m | $1.3m | $141k | |
| Interest Income (Expense), Nonoperating, Net | — | — | — | — | ($2.0m) | ($452k) | $71k | |
| Total other income (expense) | ($1.3m) | ($12.5m) | $18.0m | $2.6m | ($527k) | $837k | — | |
| Loss before income taxes | ($10.9m) | ($37.7m) | ($608k) | ($20.1m) | ($17.7m) | ($10.5m) | — | |
| Pre-Tax Income | ($10.9m) | ($37.7m) | ($608k) | ($20.1m) | ($17.7m) | ($10.5m) | ($11.1m) | |
| Income tax expenses | $64k | $56k | $32k | $14k | $22k | $25k | $26k | |
| Net loss | ($11.0m) | ($37.7m) | ($640k) | ($20.1m) | ($17.8m) | ($10.5m) | — | |
| Net Income From Continuing And Discontinued Operation | ($11.0m) | ($37.7m) | ($640k) | ($20.1m) | ($17.8m) | ($10.5m) | ($11.1m) | |
| Earnings Per Share, Basic | — | ($4.28) | ($0.61) | ($13.02) | ($3.22) | ($1.04) | ($0.98) | |
| Earnings Per Share, Diluted | — | — | — | ($13.02) | ($3.22) | ($1.04) | ($0.98) | |
| Basic | — | $8,808,233.00 | $21,139,765.00 | $1,546,297.00 | $5,516,334.00 | $10,171,921.00 | ($0.98) | |
| Diluted | — | — | $1,056,988.00 | $1,546,297.00 | $5,516,334.00 | $10,171,921.00 | ($11,085,000.00) | |
| Basic Average Shares | — | — | $1.3m | $1.5m | $5.5m | $11.6m | $10.9m | |
| Diluted Average Shares | — | — | $1.3m | $1.5m | $5.5m | $11.6m | $10.9m | |
| Additional Financial Items | ||||||||
| Change in fair value of warrant liabilities | — | ($12.8m) | $16.4m | $6.5m | $1.7m | $899k | — | |
| Diluted EPS | — | — | ($0.48) | ($13.02) | ($3.22) | ($0.90) | ($0.98) | |
| Diluted NI Availto Com Stockholders | ($11.0m) | ($37.7m) | ($640k) | ($20.1m) | ($17.8m) | ($10.5m) | ($11.1m) | |
| Normalized EBITDA | — | — | ($21.0m) | ($21.5m) | ($15.9m) | ($10.1m) | ($9.8m) | |
| Normalized Income | — | — | ($17.9m) | ($22.5m) | ($18.8m) | ($11.2m) | ($10.9m) | |
| Other Gand A | — | $37.2m | $35.9m | $39.1m | — | — | — | |
| Other Special Charges | — | — | — | ($7.5m) | $316k | — | — | |
| Reconciled Depreciation | — | — | $1.2m | $1.1m | $1.1m | $868k | $836k | |
| Selling General And Administration | — | — | $35.9m | $39.1m | $33.8m | $38.4m | — | |
| Special Income Charges | — | — | $3.8m | $7.4m | ($316k) | $0 | ($392k) | |
| Tax Effect Of Unusual Items | — | — | $4.6m | $635k | $284k | $189k | ($103k) | |
| Tax Provision | $64k | $56k | $32k | $14k | $22k | $25k | $26k | |
| Tax Rate For Calcs | — | — | $0 | $0 | $0 | $0 | $0 | |
| Costs and Expenses | — | — | — | — | $54.5m | $53.1m | — | |
| Operating Expense | — | — | $35.9m | $39.2m | $35.9m | $42.1m | $44.1m | |
| Total Unusual Items | — | — | $21.9m | $3.0m | $1.4m | $901k | ($258k) | |
| Total Expenses | — | — | $51.1m | $56.6m | $54.5m | $53.1m | $53.9m | |
| Total Other Finance Cost | — | — | $8k | $92k | $41k | — | ($1.6m) |